ASST vs MSTR: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
MSTR is the larger of the two ($51.12B market cap): the incumbent the market prices for continued execution (7.01x forward earnings, beta 3.61). ASST is the smaller challenger ($2.64B), cheaper on forward earnings (1.09x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ASST vs MSTR: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ASST | MSTR | What it tells you |
|---|---|---|---|
| Market cap | $2.64B | $51.12B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 1.09 | 7.01 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 13.31 | 3.61 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 55% of range | 25% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.42 | 0.92 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: ASST is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ASST and MSTR affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ASST and MSTR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ASST and MSTR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Strive (ASST) do?
Strive, Inc. (Nasdaq: ASST) is a Dallas-based company that pairs an asset-management business with a bitcoin-treasury strategy. It exists in its current form because Strive, the asset manager co-founded by Vivek Ramaswamy in 2022, reverse-merged into a small public company called Asset Entities and kept Asset Entities' Nasdaq ticker, ASST. Shareholders approved the merger in 2025, and the combined entity was renamed Strive, Inc. The legacy asset-management arm had grown to roughly $2.0 billion in AUM across about 13 ETFs (index, energy, thematic, and fixed-income strategies) by the end of 2024, marketed around Ramaswamy's anti-ESG, shareholder-value positioning. Matt Cole is CEO and Chairman.
What does Strategy Inc (MSTR) do?
Strategy Inc, which traded as MicroStrategy until an August 2025 rebrand, began as an enterprise business-intelligence and analytics software vendor and still sells that software (now branded around its AI-powered Strategy One platform). Since 2020 the company has pivoted almost entirely toward accumulating bitcoin as its primary treasury reserve asset, funding purchases through convertible notes, several classes of preferred stock (STRK, STRF, STRD, STRC) and at-the-market common equity sales. As of early July 2026 it held roughly 843,000 to 847,000 BTC at an average cost near $66,000 per coin, about 4% of all bitcoin, making it the largest corporate bitcoin holder in the world. It kept raising capital after that, including more than $2 billion of common stock sold in August 2026.
ASST vs MSTR: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ASST drivers: Asset-management franchise; Bitcoin-treasury accumulation.
- MSTR drivers: Leveraged bitcoin exposure; Capital-markets machine.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: ASST is a highly speculative stock whose value moves directly with the price of bitcoin, so a sharp drop in bitcoin can hit the shares harder than the coin itself; the trailing net loss of about $975 million shows how bitcoin marks flow through reported results. For MSTR, the overwhelming risk is bitcoin price: a large drawdown in BTC would hit both the asset value and the leveraged equity far harder, and the company has reported net losses of ~$12.8 billion in Q1 2026 and ~$8.6 billion in Q2 2026, mostly non-cash bitcoin markdowns.
ASST or MSTR: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ASST if you believe its drivers more; MSTR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ASST and MSTR guides.
ASST vs MSTR: the full fundamentals
ASST. ASST is valued on its bitcoin strategy and treasury, not on conventional earnings: trailing revenue is under $10 million, so price-to-sales and P/E figures are not meaningful. In mid-October 2026 the market value of the common stock sat somewhat below the value of the bitcoin it holds, before accounting for the new preferred stock, which ranks ahead of common shareholders. Figures here change frequently as the company buys more bitcoin and issues securities; verify against Strive's investor relations page and SEC filings before relying on them.
MSTR. Traditional earnings multiples do not describe Strategy well because quarterly results are dominated by non-cash bitcoin mark-to-market swings: net losses of ~$12.8 billion in Q1 2026 and ~$8.6 billion in Q2 2026 on about $120 million of quarterly software revenue. Investors instead watch the market value of its bitcoin, the mNAV premium or discount to those coins, and the size of the debt and preferred obligations. A ~$59 billion market cap against roughly $69 billion of bitcoin implies the common equity trades below the coins' value before netting debt and preferreds; Q3 2026 results are due October 29.
Headline figures (approximate, October 2026): ASST shows bitcoin held ~32,773 BTC (~$2.73 billion) as of mid-October 2026, up from ~19,864 in late June, market capitalization ~$2.47 billion at $24.47 per share (Oct 16, 2026), latest bitcoin purchase 3,311 BTC for ~$280 million (Oct 5-9, 2026), average ~$84,500 per coin, sats preferred 7 million shares of 15% perpetual preferred at $90, ~$630 million gross, closing Oct 20, 2026; MSTR shows bitcoin held ~843,000-847,000 BTC (early July 2026 count; ~4% of supply), avg btc cost basis ~$66,000 per coin (~$33.1B total), btc holdings value ~$69B at ~$81,000 per bitcoin (mid-October 2026), software revenue (quarterly) ~$122M (Q2 2026); ~$498M TTM, +7% YoY.
The bottom line: ASST vs MSTR
ASST and MSTR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ASST and MSTR exposure against your real portfolio. It is not an investment adviser.
Wondering how ASST or MSTR fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Strive
Ask Walnut's AI anything about ASST and see how it fits what you own.
FAQ
What is the difference between ASST and MSTR?
+
Strive, Inc. Strategy Inc, which traded as MicroStrategy until an August 2025 rebrand, began as an enterprise business-intelligence and analytics software vendor and still sells that software (now branded around its AI-powered Strategy One platform). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ASST or MSTR the better stock?
+
Neither is universally better. MSTR is the larger incumbent; ASST is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ASST or MSTR?
+
On forward P/E (as of November 2026), ASST trades at 1.09x and MSTR at 7.01x, so ASST is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ASST and MSTR?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ASST vs MSTR?
+
ASST: ASST is a highly speculative stock whose value moves directly with the price of bitcoin, so a sharp drop in bitcoin can hit the shares harder than the coin itself; the trailing net loss of about $975 million shows how bitcoin marks flow through reported results. Funding the bitcoin strategy through repeated PIPE, warrant and now preferred issuance is dilutive or adds senior claims: the 15% SATS preferred commits Strive to about $13.50 a share in annual dividends on 7 million shares ahead of common holders. The stock can trade at a large premium or discount to the net asset value of the bitcoin it holds, and that gap can swing violently with sentiment, as the 19% one-month drop after an 88% three-month run illustrates. Concentration in a single founder's brand, evolving regulation of crypto and bitcoin-treasury vehicles, and the unproven nature of the alpha-generating claims add further risk. MSTR: The overwhelming risk is bitcoin price: a large drawdown in BTC would hit both the asset value and the leveraged equity far harder, and the company has reported net losses of ~$12.8 billion in Q1 2026 and ~$8.6 billion in Q2 2026, mostly non-cash bitcoin markdowns. The debt and preferred stack carries interest and dividend obligations that must be serviced regardless of bitcoin's price, and the company has at times sold small amounts of BTC to meet preferred dividends. The mNAV premium can collapse, removing the accretive-issuance advantage and pressuring the share price independently of bitcoin. Heavy reliance on continual capital raises means dilution and refinancing risk, and the software business is too small to offset a serious digital-asset decline. Index exclusion is now a specific, dated risk: if MSCI's final list on November 11, 2026 includes Strategy, funds tracking MSCI indexes would be expected to sell after November 30, and similar rules elsewhere would widen that pressure. Total debt of ~$6.8 billion sits against ~$2.5 billion of cash, before the preferred stack.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ASST or MSTR; figures are approximate and dated (as of November 2026). Verify current data before investing.